Recent

% | $
Quotes you view appear here for quick access.

DryShips, Inc. Message Board

italianex1 88 posts  |  Last Activity: Feb 10, 2016 4:12 PM Member since: Jan 20, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Stay The Course Friends

    by hanskrumbholz Jan 12, 2016 11:20 AM
    italianex1 italianex1 Jan 12, 2016 12:44 PM Flag

    I just bought another 500 shares...that's all I can afford right now.If this doesn't turn north I'm screwed!

  • Reply to

    AN ARTICLE FOR THOSE OF YOU WHO HAVENT SEEN IT

    by italianex1 Jan 12, 2016 8:52 AM
    italianex1 italianex1 Jan 12, 2016 11:22 AM Flag

    RESULTS are not SPECULATIVE. RESULTS have been STELLAR....and more than likely will continue to be. That is the only speculation...

  • Reply to

    AN ARTICLE FOR THOSE OF YOU WHO HAVENT SEEN IT

    by italianex1 Jan 12, 2016 8:52 AM
    italianex1 italianex1 Jan 12, 2016 10:55 AM Flag

    This is true, but this article IS pretty straight-forward and states facts. I honestly believe that good things are in store for SGYP shareholders this year. Lets start with the NDA filing this month. Up from there hopefully! There really is so much more UPSIDE potential than downside...dontcha think!? Pretty soon the shorts will be satisfied and start covering shares and then move on to the next manipulatable stock...if that's EVEN a word! :)

    Sentiment: Strong Buy

  • Next up is Synergy Pharmaceuticals (NASDAQ:SGYP). Synergy is a small biopharmaceutical company focused on the development of novel therapies for the treatment of gastrointestinal "GI" diseases and disorders. Their proprietary GI platform is based on uroguanylin, a naturally occurring human peptide that plays a key role in regulating normal GI activity. The company has discovered and are developing two fully-owned late-stage clinical assets, plecanatide and dolcanatide, which are both analogs of a natural substance called uroguanylin.

    Plecanatide is their first-generation uroguanylin analog currently being developed for both chronic idiopathic constipation and irritable bowel syndrome with constipation. Dolcanatide is their next-generation uroguanylin analog presently being explored for ulcerative colitis.

    Plecanatide, has successfully completed two Phase 3 studies in chronic idiopathic constipation. Synergy expects to file its New Drug Application (NDA) with the FDA this month. This drug will compete against Linzess, a similar drug but one that produces more diarrhea than plecanatide saw in its recent Phase III trial results. Ironwood Pharmaceuticals (NASDAQ:IRWD) has stated it expects Linzess to achieve annual sales of $1 billion by 2020. The company also reported positive early stage trial results from dolcanatide today.

    The stock soared to over $10.00 a share early this summer on the plecanatide trial results but is back down to under $4.00 a share and sports of a market capitalization of under $500 million. The extent of the pullback is surprising given the company has been mentioned as a buyout candidate, will soon have its first commercial drug on the market and has a median price target of $11.00 a share from the five analysts that cover the company. When sentiment improves on the market as well as the high beta biotech sector, Synergy should start the long climb back to its previous highs.

    Sentiment: Strong Buy

  • italianex1 by italianex1 Jan 11, 2016 1:53 PM Flag

    When I bought this 6 or 7 months ago I thought it would have made me fairly wealthy by now. Quite the CONTRARY. UGGGGGGGGGGGHHHHHHHH I don't feel well.

  • Wanting to sell so bad cause you can't take it any more..that's what I've done...only to see all the $$ I would've made 6 months later if I had just been patient. SGYP is a winner. Just HOLD ON TO YOUR SHARES don't take the loss....It's only on paper right now!

    Sentiment: Strong Buy

  • Good new, finally SOME sort of positive PR....up pre-market.....the SLAMMMMMMED DOWN? anyone?

    Sentiment: Strong Buy

  • You better be careful! You don't want to get left behind when the train leaves the station so to speak.

    Sentiment: Strong Buy

  • I have no choice but to hold on for the ride. I think it is going to be a wild and sickly ride, but I think it will be worth holding on.I suggest all longs do the same and don't be scared into selling. DONT TAKE THE LOSSES!! NOthing has changed as far as we know. Good things on the horizon. Its the stock game. YOu have to have a tough stomach to play. DONT TAKE THE LOSS HOLD ON FOR DEAR LIFE!! Hope for the payday!

    Sentiment: Strong Buy

  • Reply to

    something must be up

    by jeffr6959 Jan 8, 2016 10:15 AM
    italianex1 italianex1 Jan 8, 2016 10:20 AM Flag

    If something has "leaked" as you put it...why hasn't it leaked further....we haven't heard a thing. Just scare tactics? Fear makes people sell..who knows....who knows...just hoping for some news for a slam upwards

  • italianex1 by italianex1 Jan 8, 2016 9:59 AM Flag

    Enough is enough!! THIS is getting RIDICULOUS! STRONG BUY shorts go away

    Sentiment: Strong Buy

  • Reply to

    noooo, but its not red today, why?,

    by odacas Jan 8, 2016 9:29 AM
    italianex1 italianex1 Jan 8, 2016 9:35 AM Flag

    I think you spoke too soon. BUY MORE!!!!

    Sentiment: Strong Buy

  • Good things to come......hold strong, buy MORE

    Sentiment: Strong Buy

  • Reply to

    New article out

    by italianex1 Jan 7, 2016 3:36 PM
    italianex1 italianex1 Jan 7, 2016 3:41 PM Flag

    The Bottom Line

    I liked Synergy before, and I find the stock's relatively subdued performance since then has opened a wider gap between the current price and my estimate of fair value. That makes it a considerably more interesting prospect to me today, though I'd note that there are quite a few biotechs looking cheaper these days. I don't think investors should ignore the risk that the medical constipation market fails to develop as hoped, but the risk-reward balance is a lot more interesting today.

  • italianex1 by italianex1 Jan 7, 2016 3:36 PM Flag

    For starters...:

    Summary

    •Positive Phase III results confirm the efficacy of plecanatide and highlight what could be a very significant tolerability advantage for Synergy over Allergan/Ironwood.

    •A key concern remains; building revenue in a market that is potentially large, but heretofore largely untapped by prescription pharmaceuticals, and doing it on a reasonable budget.

    •De-risking plecanatide in chronic constipation and increasing my market share estimate, while accounting for higher dilution, boosts my fair value over $9.

    By Stephen D. Simpson, CFA

    I can't really complain with how the Synergy Pharmaceuticals (NASDAQ:SGYP) story has developed. When I last wrote about the stock in April, I calculated a fair value of just under $6 with the shares trading at around $4 at the time. Since then, the shares have moved up $1 (up about 25%), though there was a big move up to $10 in the meantime as investors reacted very positively to strong Phase III data on the company's lead drug.

    Since then, I think reality has set in and dragged the shares down with it. Medically significant constipation (by which I mean a condition that is persistent and not quickly relieved with OTC options) has proven to be a challenging market for Allergan (NYSE:AGN)/Ironwood (NASDAQ:IRWD) and Sucampo (NASDAQ:SCMP)/Takeda (OTCPK:TKPYY), as these companies have had to push direct-to-consumer campaigns to drive awareness. I likewise believe that investors had inflated expectations of an acquisition, and impatience with that process has disappointed some shareholders (or former shareholders).

    I do believe that Allergan et al are slowly chipping away at the awareness issue, and that by virtue of its solid efficacy and better tolerability, Synergy can reap the benefits of these early market-building exercises. My fair value estimate has nearly doubled as the successful Phase III results for plecanatide significantly de-risked the value and I believe the company's efficacy/safety

  • Reply to

    What was that

    by mrbigcfo Jan 7, 2016 1:49 PM
    italianex1 italianex1 Jan 7, 2016 2:36 PM Flag

    SO SO true.

    Sentiment: Strong Buy

  • Reply to

    this stock has ruined my life, sold all my shares

    by odacas Jan 7, 2016 1:46 PM
    italianex1 italianex1 Jan 7, 2016 2:22 PM Flag

    That is a GREAT idea..don't sell at these levels!!! BUY IT BACK!!!

    Sentiment: Strong Buy

  • The stock market AS A WHOLE IS DOWN and down BIG. Just hold the fort. DONT sell your shares to the shorts who are only getting richer. OUr day will come. You have to believe this. There's really NO reason why the NDA shouldn't be favorable. Unless the whole thing is just a scamalama.....which, I guess, is always possible. LOL....You can't sell at these levels....just have to have patience!

    Sentiment: Strong Buy

  • Reply to

    Why is SGYP getting slaughtered so bad?

    by italianex1 Jan 6, 2016 10:10 AM
    italianex1 italianex1 Jan 6, 2016 10:58 AM Flag

    That's what everyone keeps saying....why is SGYP such an easy target? (Especially when we could literally "triple" from this point ..... "any day now"??? Sounds a little risky to be messing around with to me!

    Sentiment: Strong Buy

  • If the prospects are favorable. It makes no sense and its making me ill.

    Sentiment: Strong Buy

DRYS
0.107+0.005(+5.23%)Feb 12 3:59 PMEST